EUVIMEDEUVIMED entdecken
Crossref

Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen

Jiaming Zhuo, Yueqi Wang, Hui Hui, Changjian Li, Junying Yang, Peng Zhang, Chihua Fang, Jie Tian

Acta Biomaterialia · 2023

DOI: 10.1016/j.actbio.2022.12.062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2023. Verfasst von Jiaming Zhuo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China; CAS Key Laboratory of Molecular Imaging…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Glypicans, Liver Cirrhosis. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most hepatocellular carcinomas (HCCs) occur in cirrhotic livers, but unequivocal diagnosis of early HCC from the fibrotic microenvironment remains a formidable challenge with conventional imaging strategies, mainly because of the massive fibrotic collagen deposition leading to hepatic nodules formation and dysfunction of contrast agent metabolism. Here, we developed a "sweep-and-illuminate" imaging strategy, pre-degrade hepatic fibrotic collagen with collagenase I conjugated human serum albumin (HSA-C) and then targeting visualize HCC lesion with GPC3 targeting nanoparticles (TSI NPs, TJ2 peptide-superparamagnetic iron oxide-indocyanine green) via fluorescence imaging (FLI) and magnetic particle imaging (MPI). TSI NPs delineated a clear boundary of HCC and normal liver, and the tumor-to-background ratios (TBRs) detected by FLI and MPI were 5.43- and 1.34-fold higher than the non-targeted group, respectively. HSA-C could degrade 24.7% fibrotic collagen, followed by 27.2% reduction of nonspecific NPs retention in mice with liver fibrosis. In a pathological state in which HCC occurs in the fibrotic microenvironment, HSA-C-mediated pre-degradation of fibrotic collagen reduced background signal interference in fibrotic tissues and enhanced the intratumoral uptake of TSI NPs, resulting in the clear demarcation between HCC and liver fibrosis, and the TBR was increased 2.61-fold compared to the group without HSA-C pretreatment. We demonstrated the feasibility of combined pre-degradation of fibrotic collagen and application of a GPC3-targeted FLI/MPI contrast agent for early HCC identification, as well as its clinical value in the management of patients with advanced liver fibrosis. STATEMENT OF SIGNIFICANCE: Given that liver fibrosis hinders early detection and treatment options of hepatocellular carcinomas (HCCs), we report a "sweep-and-illuminate" imaging strategy to enhance the efficiency of HCC identification by modulating the irreversible liver fibrosis. We first "sweep" nonspecific interference of contrast agent by pre-degrading fibrotic collagen with human serum albumin-carried collagenase I (HSA-C); and then specifically "illuminate" HCC lesions with GPC3-targeted-SPIO-ICG nanoparticles (TSI NPs). HSA-C can degrade 24.7% fibrotic collagen, followed by 27.2% reduction of nonspecific NPs retention in mice with liver fibrosis. Furthermore, in HCC models coexisting with liver fibrosis, the combined application of HSA-C and TSI NPs can clarify the demarcation between HCC and liver fibrosis with a 2.61-fold increase in the tumor-to-background ratio. This study may expand the potential of combinatorial biomaterials for early HCC diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularGlypicansLiver CirrhosisAnimalsHumansMiceCollagenCollagenasesContrast MediaLiverLiver NeoplasmsSerum Albumin, HumanTumor Microenvironment

Stichwörter der Autor:innen

Fluorescence imagingGlypican-3Hepatocellular carcinomaLiver fibrosisMagnetic particle imaging

Substanzen

CollagenCollagenasesContrast MediaGlypicansGPC3 protein, humanSerum Albumin, Human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China; CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chines Academy of Sciences, Beijing, 100190…
  • CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chines Academy of Sciences, Beijing, 100190, China.
  • CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chines Academy of Sciences, Beijing, 100190, China; University of Chinese Academy of Sciences, Beijing 100049, China.
  • CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chines Academy of Sciences, Beijing, 100190, China; School of Engineering Medicine & School of Biological Science and Medical Engineering, Beihang Univer…
  • Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China; Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou 510280, China.
  • Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China; Guangdong Provincial Clinical and Engineering Center of Digital Medicine, Guangzhou 510280, China; Pazhou Lab…

Förderung

  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Chinese Academy of Sciences
  • Chinese Academy of Sciences Key Technology Talent Program
  • CAS Youth Innovation Promotion

Zitieren

APA

Zhuo, J., Wang, Y., Hui, H., Li, C., Yang, J., Zhang, P., Fang, C., & Tian, J. (2023). Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2022.12.062

Vancouver

Zhuo J, Wang Y, Hui H, Li C, Yang J, Zhang P, et al. Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. Acta Biomaterialia. 2023. doi:10.1016/j.actbio.2022.12.062

BibTeX
@article{Zhuo2023,
  author = {Zhuo, Jiaming and Wang, Yueqi and Hui, Hui and Li, Changjian and Yang, Junying and Zhang, Peng and Fang, Chihua and Tian, Jie},
  title = {Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen},
  journal = {Acta Biomaterialia},
  year = {2023},
  doi = {10.1016/j.actbio.2022.12.062}
}
Kostenlos starten →